Vaxxinity Has a Rough Public Debut
Vaxxinity (NASDAQ: VAXX), a clinical-stage biotech, recently IPOed for a price lower than the previously announced range. In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss the prospects for the company's experimental COVID-19 vaccine and its Alzheimer's disease therapy.
Given how late Vaxxinity is to the COVID-19 vaccine enterprise, the history of failures in developing therapies for Alzheimer's disease, and the fact that the company's most advanced programs are phase 2 clinical studies, it's not surprising that there isn't as much investor interest as initially hoped for.
Source Fool.com
